zh-twzhen
zh-twzhen

Oneness Biotech Co., Ltd., has been granted the Brazil Good Manufacturing Practice (B-GMP) certification for Bonvadis from Brazil ANVISA.

2023

Date

Title

2023-04-28

Announcement of the Phase 1 clinical trial data of SNS812, a broad-spectrum antiviral siRNA for COVID-19 developed jointly by Oneness and Microbio (Shanghai) Co.,Ltd.

>
2023-04-27

Oneness was notified today that Bonvadis Cream for scar management has been granted import license in Europe.

>
2023-04-18

Oneness announce the important resolutions of the 2023 Annual General Shareholders’ Meeting

>
2023-04-12

Announce the change of the corporate governance officer.

>
2023-04-12

The board of directors of the Company approved removal of the noncompete clause for managers.

>
2023-03-24

Oneness announces the information about the investor’s conference of 2023 Q1.

>
2023-03-22

Oneness received Medical Devices Export License approvals by TFDA on Bonvadis Topical Cream and Bonvadis Cream. The certificate will be collected accordingly.

>
2023-03-15

Oneness Biotech Co., Ltd., Nanchou Plant had been granted with Medical Devices Quality Management System (QMS) Approval.

>
2023-03-14

Oneness was notified today that Bonvadis, the wound care topical cream has obtained import license in New Zealand.

>
2023-02-24

Oneness Board of Directors resolved to convene the Annual Shareholders’ Meeting of 2023.(additional matters)

>
2023-02-24

The board of directors of Oneness approved a resolution on issuance of the Restricted Stock Awards (RSA) of 2023.

>
2023-02-24

The Board of Directors resolved to the new common share issuance through the increase of capital by capitalization of earnings and capital surplus

>
2023-02-24

The Board of Directors resolved to distribute dividends.

>
2023-02-24

The Company’s 2022 consolidated financial statements have been approved by the Board of Directors

>
2023-02-18

Oneness was notified today that Bonvadis, the wound care topical cream has obtained import license in India.

>